Notably, there was no association between FTO expression and molecular features that affect the prognosis of NPM1-mutated AML (FLT3-ITD, and FLT3-ITD and DNMT3A mutations) (Figure 1G). This evidence concerns the gene FTO and acute myeloid leukemia.